Novo Nordisk will almost certainly launch with: A savings card for patients with commercial insurance (reducing costs to $25$50/month in many cases) A patient assistance program for income-qualifying uninsured patients Possible direct-to-consumer pricing through NovoCare Pharmacy, similar to Wegovys $349/month self-pay model
Google doesn't need to run your JavaScript to understand your page
My patient is refusing a drug studied in 170,000 people because of side effects that a 124,000-person analysis just confirmed do not exist while injecting a compound studied in 14 humans, from unregulated sources, based on the recommendation of someone who profits from selling it
Several peptides being studied have mechanisms that directly address this core problem: they promote new blood vessel formation (angiogenesis), reduce the inflammatory cascade that accelerates disc breakdown, and stimulate the cellular repair processes needed to rebuild damaged disc structures
The product page itself avoids therapeutic claims, dosing recommendations for human use, and any consumer-health positioning that would conflict with Canadian regulatory expectations